Search the Newsreel

Wells Fargo cuts Metagenomi stock price target on higher R&D costs

Wells Fargo has lowered its price target for Metagenomi Inc (NASDAQ:MGX) shares to $7.00 from $9.00, while maintaining an Overweight rating, citing higher-than-expected research and development expenses and a larger net loss per share in Q2 2026. Despite the stock trading down 24% year-to-date, …

Metagenomi Therapeutics reports $27.5M loss in Q2 2026

Metagenomi Therapeutics (NASDAQ: MGX) reported a significant net loss of $27.482 million in Q2 2026, widening from the previous year, and missed analyst EPS estimates. The company's collaboration revenue dropped sharply to $(0.257) million from $8.513 million in Q2 2025. Despite these financial setbacks, …

Metagenomi Therapeutics: Q2 Earnings Snapshot

Form 8K Metagenomi Inc For: 10 August By Investing.com

This article from Investing.com reports that Metagenomi Inc. filed a Form 8K on August 10th. The brief piece includes a stock symbol (MGX) and indicates the stock was trading at 0.00%. The content mainly consists of standard financial market data, including various indices, commodities, …

Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M

Metagenomi Therapeutics (NasdaqGS:MGX) Stock Forecast & Analyst Predictions

Metagenomi Therapeutics (MGX) faces significant financial challenges, with forecasted declines in revenue and earnings. Analyst consensus shows a downward trend in revenue estimates and price targets, alongside consistent net losses. The company has also experienced volatility in its stock price and is currently facing …

Metagenomi Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Metagenomi Therapeutics Inc is projected to report a loss of 57 cents per share. This earnings preview from Refinitiv indicates the company's expected financial performance. The full article is available on TradingView, offering unlimited access to news from various sources.

MGX|Metagenomi Inc|Price:1.215|Chg%:+0.005

Metagenomi Inc (MGX) has a TradingKey Stock Score indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. The company, focused on precision genetic medicine, has seen high institutional ownership and multiple "Buy" …

Metagenomi Inc (MGX) Valuation: PE, PB & Fair Value Analysis

Metagenomi Inc (MGX) currently has a valuation score of 8.48, placing it 118th out of 385 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -0.53, which is 5.79% below its recent high and 1178.03% above its recent low. Key valuation …

Metagenomi Therapeutics, Inc. Revenue Breakdown – NASDAQ:MGX

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) generated $25.21 million in revenue last year, with its Ionis segment contributing the most at $24.62 million. This marks a decrease from the previous year's total revenue of $30.44 million. The United States was the primary geographic contributor, accounting for …

TradingKey

This article provides a detailed cash flow statement for Metagenomi Inc (MGX), including operating, investing, and financing cash flows, presented quarterly and annually. It includes multi-year financial data, percentage changes, and a FAQ section clarifying financial terms like operating cash flow, investing cash flow, …

Metagenomi Inc (MGX) Balance Sheet Analysis

This article provides a detailed quarterly and annual balance sheet analysis for Metagenomi Inc (MGX). It presents key financial metrics such as cash, assets, liabilities, and shareholders' equity over several fiscal quarters. The content also includes an FAQ section addressing important balance sheet metrics …

MGX|Metagenomi Inc|Price:1.200|Chg%:-0.020

Metagenomi Inc. (MGX) is a precision genetic medicine company focused on developing curative therapeutics using its comprehensive metagenomics-derived toolbox, including programmable nucleases and CRISPR-associated transposases. The company employs AI and its metagenomics platform to create genetic medicines. As of Q1 2026, 172 institutions hold …

Metagenomi Therapeutics (MGX) Proxy filing Summary

Metagenomi Therapeutics (MGX) held its annual meeting virtually on June 9, 2026, where shareholders voted on the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The board recommended voting for both proposals. The company …

Metagenomi Therapeutics (MGX) Q1 2026 earnings summary

Metagenomi Therapeutics (MGX) reported Q1 2026 earnings, focusing on its in vivo genome editing pipeline and a strategic reprioritization of its lead programs. The company's lead program, MGX-001 for hemophilia A, showed promising preclinical data with an IND submission planned for Q4 2026. Financial …